Dyne Therapeutics announces program updates, analysts maintain Buy rating and $50 price target

From Yahoo Finance: 2025-06-18 09:45:00

Dyne Therapeutics announced updates for DYNE-101 program for myotonic dystrophy type 1, including FDA alignment for accelerated approval pathway and updated data for the 6.8 mg/kg dose. Analysts believe FDA confirmation offsets potential delay in BLA submission, maintain Buy rating and $50 price target. Stock price seen as attractive entry point.

Source: TheFly

For more information on Dyne Therapeutics, visit the company’s website.

Disclaimer & Disclosure: This article is for informational purposes only. Please consult with a financial advisor before making any investment decisions.

Read more: Dyne at ‘attractive entry point’ following pullback, says Chardan